10 completed. 10 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Leflunomide: new trials by email Literature Review of Leflunomide trials Research Report on Leflunomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders Leflunomide - Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder | Phase 2 | Completed | City of Hope Medical Center | 1 | 2021-05-05 | 2023-12-05 |
| Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Best Practice, Leflunomide, Placebo Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 2 | 2021-01-07 | 2024-07-03 |
| Leflunomide in Previously Treated Metastatic Triple Negative Cancers Leflunomide - Breast Neoplasms, Breast Diseases | Phase 1 / Phase 2 | Completed | Joseph Sparano | 17 | 2019-04-16 | 2026-03-19 |
| Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 12 | 2015-12-02 | 2023-10-10 |
| A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis MLTA3698A, adalimumab, leflunomide - Rheumatoid Arthritis | Phase 2 | Completed | Genentech, Inc. | 211 | 2010-11-01 | 2016-11-02 |
| Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study anakinra, comparators - Adult-Onset Still's Disease | Phase 2 | Completed | University of Helsinki | 23 | 2005-12-01 | 2017-03-06 |
| Leflunomide in Systemic Lupus Erythematosus Leflunomide - Systemic Lupus Eythematosus (SLE) | Phase 2 | Completed | Sanofi | 27 | 2003-01-01 | 2008-03-28 |
| Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer leflunomide, mitoxantrone hydrochloride, prednisone - Prostate Cancer | Phase 2 / Phase 3 | Completed | Pfizer | 1999-08-01 | 2012-09-11 | |
| Leflunomide to Treat Uveitis Leflunomide - Uveitis | Phase 2 | Completed | National Eye Institute (NEI) | 16 | 1999-03-01 | 2008-03-04 |
| Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse leflunomide - Brain and Central Nervous System Tumors | Phase 2 | Completed | Pfizer | 60 | 1998-12-01 | 2012-09-13 |
Arthritis, Rheumatoid (1) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Diseases (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Inflammation (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Prostatic Neoplasms (1) · Still's Disease, Adult-Onset (1) · Triple Negative Breast Neoplasms (1) · Uveitis (1)
City of Hope Medical Center (3) · Pfizer (2) · Genentech, Inc. (1) · Joseph Sparano (1) · National Eye Institute (NEI) (1) · Sanofi (1) · University of Helsinki (1)
United States (8) · Bulgaria (1) · Canada (1) · Chile (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Mexico (1) · Peru (1) · Poland (1) · Romania (1) · Spain (1) · Sweden (1)
Alison L. Hannah, MBBS (1) · Christiane Querfeld (1) · Dan C Nordstrom, MD, PhD (1) · Iris Chan (1) · John C. Davis, Jr., M.D., M.P.H. (1) · Joseph Sparano, MD (1) · Mack H. Mabry, MD (1) · Michael Rosenzweig (1) · Sanjeet S Dadwal (1)
PMID 22859346, PMID 25359150, PMID 32268821
P30CA033572 (2), 2005 (1)